Research programme: B-Raf kinase inhibitors - PfizerAlternative Names: PF-04880594; WYE-130600
Latest Information Update: 14 Sep 2011
At a glance
- Originator Pfizer
- Class Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Proto oncogene protein b raf inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Sep 2011 Preclinical development is ongoing in US
- 26 Mar 2009 Early research in Cancer in USA (unspecified route)